Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-08-26Clinical Trial Update: Long-Duration Stimulant Treatment Study of ADHD in Young Children [Phase 4]
Phase 4 trial update on long-duration stimulant treatment for ADHD in young children; study completed with results posted.
-
FDA approval · 2020-08-19FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' methylphenidate hydrochloride generic under an original application (ANDA 205135).
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Early Interventions in Children With Attention Deficit/Hyperactivity Disorder [Phase 4]
Phase 4 trial update on early interventions for children with attention deficit/hyperactivity disorder.
-
FDA approval · 2020-08-04FDA Approved: CLONIDINE HYDROCHLORIDE — Supplemental Application (BluePoint Laboratories)
The FDA approved BluePoint Laboratories' supplemental application for clonidine hydrochloride (ANDA), granting a supplemental approval for t…
-
FDA approval · 2020-07-29FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Dr.Reddys Laboratories Inc)
FDA approves the original ANDA for methylphenidate hydrochloride from Dr. Reddy's Laboratories, making a generic ADHD treatment available.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-07-24Clinical Trial Update: Software Treatment for Actively Reducing Severity of ADHD [NA]
A completed clinical trial evaluating a software-based treatment intended to actively reduce severity of ADHD. Results have been posted.
-
CLINICAL_TRIALS research · 2020-07-24Clinical Trial Update: Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach [Phase 4]
Phase 4 clinical trial investigating imaging stimulants and non-stimulants for ADHD using a network-based approach; study completed with res…
-
FDA approval · 2020-07-23FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Solco Healthcare US,LLC)
FDA approved Solco Healthcare US, LLC's original application for methylphenidate hydrochloride, a generic medication indicated for ADHD and …
-
CLINICAL_TRIALS trial_result · 2020-06-24Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. [Phase 3]
Phase 3 trial evaluating dasotraline for ADHD in children aged 6-12; study completed with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-06-19Clinical Trial Update: Treatment of Children With ADHD Who do Not Fully Respond to Stimulants [Phase 2]
Phase 2 trial updating treatment for children with ADHD who do not fully respond to stimulants; study terminated with results posted in 2020…
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Methylphenidate for Attention Problems After Pediatric TBI [Phase 4]
Phase 4 trial assessing methylphenidate for attention problems after pediatric traumatic brain injury has completed with results posted.
-
FDA approval · 2020-06-04FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (QUAGEN PHARMACEUTICALS LLC)
FDA approved the Original Application for methylphenidate hydrochloride from Quagen Pharmaceuticals LLC, making a generic methylphenidate hy…
-
FDA approval · 2020-05-27FDA Approved: CLONIDINE HYDROCHLORIDE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for clonidine hydrochloride from Actavis Pharma, Inc. to bring a generic version of the antihype…
-
FDA approval · 2020-05-21FDA Approved: CLONIDINE HYDROCHLORIDE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for clonidine hydrochloride from Somerset Therapeutics, LLC, under an ANDA, indicating approval of a…
-
FDA approval · 2020-05-21FDA Approved: GUANFACINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA granted approval of a supplemental application for guanfacine from Actavis Pharma, enabling the generic version to be marketed. This…
-
FDA approval · 2020-05-21FDA Approved: GUANFACINE — Supplemental Application (Sun Pharmaceutical Industries, Inc)
FDA approved a supplemental application for guanfacine from Sun Pharmaceutical Industries (ANDA205689).
-
FDA approval · 2020-05-21FDA Approved: CLONIDINE HYDROCHLORIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for clonidine hydrochloride by Lupin Pharmaceuticals, Inc., under the ANDA framework.
-
FDA approval · 2020-04-10FDA Approved: METHYLPHENIDATE HCL — Original Application (Patrin Pharma, Inc.)
FDA approved Patrin Pharma, Inc.'s original ANDA for methylphenidate hydrochloride (generic) for the treatment of attention-deficit/hyperact…
-
CLINICAL_TRIALS trial_result · 2020-04-07Clinical Trial Update: Impact of Strattera and Behavior Therapy on the Home and School Functioning of Children With ADHD [Phase 4]
Phase 4 trial evaluating the impact of Strattera (atomoxetine) and behavior therapy on home and school functioning in children with ADHD.
-
FDA approval · 2020-04-03FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Oryza Pharmaceuticals Inc.)
FDA approved the generic combination product containing dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and …
-
FDA approval · 2020-03-30FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Ascend Laboratories, LLC)
FDA approved an original ANDA for methylphenidate hydrochloride (generic) manufactured by Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. [Phase 3]
Phase 3 study assessing efficacy and safety of dasotraline in children aged 6-12 with ADHD in a simulated classroom setting; trial completed…
-
CLINICAL_TRIALS trial_result · 2020-03-18Clinical Trial Update: Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders [Phase 4]
Phase 4 trial comparing methylphenidate to risperidone for children/adolescents with ADHD and disruptive disorders; study terminated.
-
FDA approval · 2020-03-11FDA Approved: AMPHETAMINE SULFATE — Original Application (Solco Healthcare US, LLC)
FDA approves the original application for amphetamine sulfate (generic) to be marketed by Solco Healthcare US, LLC.
-
CLINICAL_TRIALS trial_result · 2020-02-28Clinical Trial Update: The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit Hyperactivity Disorder in Children [NA]
A completed clinical trial evaluating the effects of physical training and omega-3 consumption on Attention Deficit Hyperactivity Disorder i…